Promyelocytic leukemia protein is required for gain of function by mutant p53.
暂无分享,去创建一个
G. Blandino | Y. Haupt | S. Haupt | S. Di Agostino | A. Damalas | M. Voorhoeve | O. Alsheich-Bartok | I. Mizrahi
[1] E. Appella,et al. PML enhances the regulation of p53 by CK1 in response to DNA damage , 2008, Oncogene.
[2] T. Iwakuma,et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. , 2008, Genes & development.
[3] E. White,et al. Does control of mutant p53 by Mdm2 complicate cancer therapy? , 2008, Genes & development.
[4] D. Schiff,et al. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. , 2008, Cancer research.
[5] Erik Meulmeester,et al. p53: a guide to apoptosis. , 2008, Current cancer drug targets.
[6] G. Blandino,et al. Mutant p53 proteins: Between loss and gain of function , 2007, Head & neck.
[7] G. Blandino,et al. Mutant p53: an oncogenic transcription factor , 2007, Oncogene.
[8] T. Iwakuma,et al. Crippling p53 activities via knock-in mutations in mouse models , 2007, Oncogene.
[9] Giulia Piaggio,et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. , 2006, Cancer cell.
[10] T. Stamminger,et al. Evidence for a Role of the Cellular ND10 Protein PML in Mediating Intrinsic Immunity against Human Cytomegalovirus Infections , 2006, Journal of Virology.
[11] R. Everett,et al. PML Contributes to a Cellular Mechanism of Repression of Herpes Simplex Virus Type 1 Infection That Is Inactivated by ICP0 , 2006, Journal of Virology.
[12] N. Gueven,et al. The complexity of p53 stabilization and activation , 2006, Cell Death and Differentiation.
[13] Jason A. Koutcher,et al. Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.
[14] G. Blandino,et al. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression , 2006, Oncogene.
[15] R. Mantovani,et al. Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters , 2005, Molecular and Cellular Biology.
[16] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[17] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[18] J. Manfredi,et al. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. , 2004, Molecular cell.
[19] C. Gespach,et al. Nuclear bodies and compartments: functional roles and cellular signalling in health and disease. , 2004, Cellular signalling.
[20] Zigang Dong,et al. Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.
[21] P. Pandolfi,et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. , 2004, Journal of the National Cancer Institute.
[22] P. Pandolfi,et al. Promyelocytic Leukemia Protein 4 Induces Apoptosis by Inhibition of Survivin Expression* , 2004, Journal of Biological Chemistry.
[23] E. Appella,et al. Phosphorylation Site Interdependence of Human p53 Post-translational Modifications in Response to Stress* , 2003, Journal of Biological Chemistry.
[24] Pier Paolo Pandolfi,et al. The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated Inhibition and Degradation* , 2003, Journal of Biological Chemistry.
[25] P. Pelicci,et al. The PML gene is not involved in the regulation of MHC class I expression in human cell lines. , 2003, Blood.
[26] A. Dejean,et al. Deconstructing PML‐induced premature senescence , 2002, The EMBO journal.
[27] R. Bernards,et al. A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.
[28] H. Drexler,et al. Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. , 2002, Leukemia research.
[29] Pier Paolo Pandolfi,et al. The Role of PML in Tumor Suppression , 2002, Cell.
[30] G. Zambetti,et al. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. , 2001, Gene.
[31] R. Mantovani,et al. NF-Y Mediates the Transcriptional Inhibition of thecyclin B1, cyclin B2, and cdc25CPromoters upon Induced G2 Arrest* , 2001, The Journal of Biological Chemistry.
[32] V. Rotter,et al. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.
[33] P. Pandolfi,et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform , 2000, The EMBO journal.
[34] Ailan Guo,et al. The function of PML in p53-dependent apoptosis , 2000, Nature Cell Biology.
[35] Giulia Piaggio,et al. The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated , 1999, Oncogene.
[36] A. Levine,et al. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.
[37] M. Koken,et al. PML induces a novel caspase-independent death process , 1998, Nature Genetics.
[38] P. Pandolfi,et al. Role of PML in cell growth and the retinoic acid pathway. , 1998, Science.
[39] P. Pelicci,et al. Analysis of p53 gene mutations in acute myeloid leukemia , 1994, American journal of hematology.
[40] P. Pelicci,et al. Frequency of RAS and p53 mutations in acute promyelocytic leukemias. , 1993, Leukemia & lymphoma.
[41] A. Levine,et al. Gain of function mutations in p53 , 1993, Nature Genetics.
[42] V. Rotter,et al. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. , 1991, Cancer research.
[43] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.